Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study

Research Team:

Colin Simpson1, Daniel Kotz1,2,3,4*, Wolfgang Viechtbauer3, Onno C.P. van Schayck1,3, Robert West4, Dermot Ryan1, Aziz Sheikh1,3

1Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK  2Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. Department of Family Medicine, 3CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, the Netherlands. 4Cancer Research UK Health Behaviour Research Centre, University College London, London, UK. 5MHeNS School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands. 6Woodbrook Medical Centre, Loughborough.

Status: Active



Short Description:

The aim of this study is to assess the safety of varenicline using data from OPCRD. Our primary research question is: is the use of varenicline or bupropion for smoking cessation compared with NRT associated with an increased risk of cardiovascular or neuropsychiatric events?

Documents and Publications




Final Publications

Additional Material